8-K: Lifeward Ltd. Announces Record Revenue for Q4 and Full Year 2024, Focuses on Sustainable Growth

Lifeward Ltd. reports record quarterly and annual revenue, driven by strong growth in U.S. ReWalk opportunities and a strategic shift towards profitability with its 2025 Sustainable Growth Plan.

Summary

• Lifeward Ltd. announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company achieved record quarterly revenue of $7.5 million and annual revenue of $25.7 million.
• ReWalk Personal Exoskeleton sales increased by 130% in 2024, boosted by Medicare coverage.
• Lifeward launched its 2025 Sustainable Growth Plan, aiming to balance revenue growth with expense reduction to lower the non-GAAP operating loss.
• A new partnership with CorLife was established to distribute ReWalk for workers' compensation claims.
• The partnership with MYOLYN expanded to include referral sales for home use of the MyoCycle FES Cycling Therapy System.
• The company completed actions to streamline U.S. operations, including facility closures and a 35% headcount reduction since the AlterG acquisition.
• A registered direct offering was completed, raising approximately $5.0 million to fund commercial efforts and working capital.
• Revenue from ReWalk, MyoCycles, and ReStore was $2.0 million in Q4 2024, a 6% decrease year-over-year due to scheduling challenges.
• AlterG product and service revenue was $5.5 million in Q4 2024, a 17% increase driven by international demand.
• The gross margin was 24.4% in Q4 2024, but the adjusted gross margin was 45.4% on a non-GAAP basis.
• Total operating expenses were $17.1 million in Q4 2024, with adjusted operating expenses at $6.7 million on a non-GAAP basis.
• The operating loss was $15.2 million in Q4 2024, with an adjusted operating loss of $3.3 million on a non-GAAP basis.
• The net loss was $15.3 million, or $1.73 per share, for Q4 2024, with an adjusted net loss of $3.3 million, or $0.38 per share, on a non-GAAP basis.
• As of December 31, 2024, Lifeward had $6.7 million in unrestricted cash and cash equivalents.
• Cash used in operations during Q4 2024 was $4.0 million.
• On January 8, 2025, a registered direct offering raised approximately $5.0 million.
• For 2025, Lifeward expects revenue between $28 million and $30 million, with adjusted gross margins between 47% and 49%.
• Non-GAAP operating expenses are projected to be between $22 million and $23 million, resulting in a non-GAAP operating loss of $7 million to $9 million.
• The company anticipates a quarterly adjusted operating loss of approximately $1 million by the fourth quarter of 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company reports record revenue and growth in key areas like ReWalk sales, there are also concerns about increased operating expenses, net losses, and gross margin decline. The focus on a sustainable growth plan and cost reduction efforts suggests a proactive approach to addressing these challenges, balancing the positive and negative aspects.

Positives

• Lifeward achieved record quarterly and annual revenue in 2024.
• ReWalk sales saw significant growth due to Medicare coverage.
• The 2025 Sustainable Growth Plan aims to improve profitability.
• The company successfully raised capital through a registered direct offering.
• The company is streamlining operations to reduce expenses.
• The company expects revenue growth in 2025.

Negatives

• Gross margin decreased in Q4 2024 compared to Q4 2023.
• Operating expenses increased significantly in Q4 2024 due to impairment charges.
• The company reported a net loss for Q4 2024.
• Revenue from ReWalk, MyoCycles, and ReStore was down 6% compared to the prior year due to scheduling challenges and delays for initial training sessions at local clinics.
• Cash used in operations during Q4 2024 was $4.0 million.

Risks

• Uncertainties associated with clinical trials and regulatory processes could impact product development.
• The company's ability to maintain sufficient funds to meet capital requirements is a risk.
• Failure to achieve reimbursement from third-party payors could hinder growth.
• The company's limited operating history poses a risk to its ability to leverage its infrastructure.
• Cybersecurity attacks could disrupt business operations.
• The company's ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer.

Future Outlook

Lifeward expects full-year revenue in the range of $28 million to $30 million for 2025, with adjusted gross margins between 47% and 49%. The company anticipates a quarterly adjusted operating loss of approximately $1 million by the fourth quarter of 2025.

Management Comments

• Larry Jasinski, Chief Executive Officer, stated that the company made significant strides in sales driven by Medicare coverage of the ReWalk exoskeleton and expects private insurance to follow.
• Larry Jasinski mentioned that the company continues to build a robust pipeline of ReWalk cases and is focused on achieving balanced growth while strategically working towards profitability.
• Larry Jasinski expressed confidence that cost-efficient measures will enhance operational effectiveness and drive sustainable success.

Industry Context

The announcement reflects a growing trend in the medical technology industry towards innovative rehabilitation solutions and the importance of securing reimbursement coverage for these technologies. The partnership with CorLife and expansion with MYOLYN indicate a strategic focus on expanding market reach and penetration.

Comparison to Industry Standards

• Comparing Lifeward to companies like Ekso Bionics and ReWalk Robotics, Lifeward's revenue growth of 85% year-over-year is significant.
• The focus on reducing operating loss aligns with industry trends of achieving profitability in the medical device sector.
• The expansion of distribution channels through partnerships is a common strategy among medical device companies to increase market access.
• The company's gross margin of 24.4% is lower than industry averages, but the adjusted gross margin of 45.4% is more in line with competitors.
• The company's non-GAAP operating loss of $3.3 million is similar to other companies in the sector.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the revenue growth and cost reduction plans.
• Employees may be affected by the streamlining of operations and headcount reductions.
• Customers will benefit from the continued development and commercialization of innovative rehabilitation solutions.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Implement the 2025 Sustainable Growth Plan.
• Continue to build a robust pipeline of ReWalk cases.
• Focus on achieving balanced growth while strategically working towards profitability.
• Implement cost-efficient measures to enhance operational effectiveness.
• Phase in the full benefits of operating expense reductions throughout the second half of 2025.

Key Dates